Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Howard Bennett who wrote (435)	1/5/1998 5:11:00 PM
From: robwins	Respond to of 9523

Don't know if this has any bearing on the recent bump in stock price but I saw a posting in another newsgroup to the effect that someone in the FDA had been contacted and he confirmed that Viagra had indeed been approved and that marketing will begin March of '98. That posting (which I apologize for not having available) listed a phone number w/i the FDA at which this info could in fact be confirmed. I suppose if anyone's interested I could resurrect the posting and provide the number. Maybe we can get a confirmation from another observer of this group. /Rob

To: Howard Bennett who wrote (435)	1/5/1998 5:31:00 PM
From: Ibexx	Read Replies (1) \| Respond to of 9523

Howard and thread, Supposedly PFE surged today primarily because analyst Birinyi included this stock on his BUY list. The famed quantitative analyst based his recommendation upon institutional money inflow (into specific stocks) and this news item was carried by the wire shortly before 2 PM. biz.yahoo.com Enjoy.....I certainly am. Ibexx

To: Howard Bennett who wrote (435)	1/5/1998 6:23:00 PM
From: AllenP	Read Replies (1) \| Respond to of 9523

More news: Monday January 5, 2:48 am Eastern Time UK's Peptide Therap , Pfizer sign deal LONDON, Jan 5 (Reuters) - British vaccines specialist Peptide Therapeutics Group Plc said on Monday it would collaborate with U.S. pharmaceutical group Pfizer Inc for development of a veterinary allergy vaccine. According to the deal, the vaccine will be developed initially for prevention of dermatitis in dogs caused by allergy to flea bites. Pfizer will conduct and pay all costs of the research and clinical development programme for evaluating the vaccine. The U.S. company has acquired an exclusive option to a worldwide licence for the vaccine. Peptide Therapeutics had signed an alliance with British pharmaceutical company SmithKline Beecham Plc (quote from Yahoo! UK & Ireland: SB.L) last year for developing a human allergy vaccine. --------------------------------------------------------------------------------